Share Page

Multimedia

Discover NIMH: Drug Discovery and Development

October 9, 2019

One of the most exciting recent breakthroughs from research funded by the National Institute of Mental Health (NIMH) is the development of a fast-acting medication for treatment-resistant depression based on ketamine. This treatment is bringing new hope to people and families affected by major depression.

Lanie Bachmann, Winner of the 2022 NIMH Three-Minute Talks Competition March 20, 2023
Abby Vogeley, Winner of the 2022 NIMH Three-Minute Talks Competition March 20, 2023
Director’s Innovation Speaker Series: The Opioid Crisis: Disrupting the Status Quo with the HEALing Communities Study February 14, 2023
Director’s Innovation Speaker Series: Ecological Grief and Anxiety: A Healthy Response to Climate Change January 19, 2023

: Anxiety Disorders; Attention-Deficit/Hyperactivity Disorder (ADHD); Autism Spectrum Disorder (ASD); Bipolar Disorder; Borderline Personality Disorder; COVID-19; Depression; Disruptive Mood Dysregulation Disorder; Eating Disorders; Generalized Anxiety Disorder; HIV/AIDS; Obsessive-Compulsive Disorder (OCD); Panic Disorder; Post-Traumatic Stress Disorder (PTSD); Psychosis; Schizophrenia; Social Anxiety Disorder; Suicide; Traumatic Events

: Children and Adolescents; Global Mental Health; Men’s Mental Health; Military Service Members; Older Adults; Sexual and Gender Minority; Women’s Mental Health

: Basic Research; Brain Anatomy and Physiology; BRAIN Initiative; Clinical Research and Trials; Genetics; Health Disparities; Mental Health Services Research; Prevention; RDoC; Recovery Act; Research Funding; Training; Treatments

The View of the NIMH Intramural Program From the Top: An Interview with Dr. Susan Amara May 13, 2021
About NIMH April 29, 2020
Strategic Plan for Research Overview April 29, 2020
Message from the Director on the Strategic Plan for Research April 29, 2020

: Institute Announcements